"Flutamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Descriptor ID |
D005485
|
| MeSH Number(s) |
D02.065.199.420 D02.092.146.113.420
|
| Concept/Terms |
Eulexin- Eulexin
- Euflex
- Drogenil
- Eulexine
|
Below are MeSH descriptors whose meaning is more general than "Flutamide".
Below are MeSH descriptors whose meaning is more specific than "Flutamide".
This graph shows the total number of publications written about "Flutamide" by people in this website by year, and whether "Flutamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Flutamide" by people in Profiles.
-
Momb BA, Szabo GK, Mogus JP, Chipkin SR, Vandenberg LN, Miller MS. Skeletal Muscle Function Is Altered in Male Mice on Low-Dose Androgen Receptor Antagonist or Estrogen Receptor Agonist. Endocrinology. 2023 08 28; 164(10).
-
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1504-1515.
-
Toraldo G, Bhasin S, Bakhit M, Guo W, Serra C, Safer JD, Bhawan J, Jasuja R. Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking ?-catenin nuclear translocation and cross-talk with TGF-? signaling in keratinocytes. Wound Repair Regen. 2012 Jan-Feb; 20(1):61-73.
-
Mercader M, Sengupta S, Bodner BK, Manecke RG, Cosar EF, Moser MT, Ballman KV, Wojcik EM, Kwon ED. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int. 2007 Jan; 99(1):60-7.
-
Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005 Apr 07; 24(15):2474-82.
-
Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol. 2001 May; 15(5):765-82.